The CJEU issued on 9 July 2020 its judgment in the Santen C-673/18 case. The judgment, which is reviewed in more detail in our briefing (here), overturns the earlier Neurim decision and concludes that SPCs are not available for new therapeutic uses of old active ingredients.
Originally published 10 July 2020.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
